Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F25%3A00603798" target="_blank" >RIV/61388971:_____/25:00603798 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10489816 RIV/00064203:_____/25:10489816

Výsledek na webu

<a href="https://www.nature.com/articles/s41598-024-83858-7" target="_blank" >https://www.nature.com/articles/s41598-024-83858-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-024-83858-7" target="_blank" >10.1038/s41598-024-83858-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease

Popis výsledku v původním jazyce

The aim was to explore factors associated with intestinal tissue levels of anti-TNF alpha (anti-TNF), anti-TNF antibodies, and cytokines in pediatric patients with Crohn Disease (CD). In a prospective exploratory study of CD patients undergoing ileocecal resection or colonoscopy between 6/2020 and 1/2023, we analysed tissue levels of anti-TNF, anti-TNF antibodies, and cytokines (TNF-α, IL-17, IL-1β, IFN-γ) from intestinal biopsies. Mixed-effects regression models, adjusted for potential confounders,nwere used. Data from 27 CD patients (18 females, 66.7%) were analysed. Fourteen (52%) received adalimumab (ADA) and thirteen received infliximab (IFX), with a median therapy duration of 17 (IQR 4.5–41.5) months. Higher levels of free anti-TNF were found in macroscopically inflamed tissue compared to non-inflamed tissue (β=3.42, 95% CI 1.05–6.10). No significant association was found between serum and tissue anti-TNF levels (β= −0.06, 95% CI −0.70–0.58). Patients treated longernwith anti-TNF had increased IL-17 levels (β=0.19, 95% CI 0.05–0.33), independent of disease duration and age. IFN-γ levels were linked with both follow-up duration and anti-TNF length. Our study shows significantly higher free drug levels in inflamed tissue. Long-term anti-TNF treatment has been linked to increased IL-17 levels, suggesting a possible impact on the cytokine response pathway. We did not observe a relationship between serum and tissue anti-TNF levels.

Název v anglickém jazyce

Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease

Popis výsledku anglicky

The aim was to explore factors associated with intestinal tissue levels of anti-TNF alpha (anti-TNF), anti-TNF antibodies, and cytokines in pediatric patients with Crohn Disease (CD). In a prospective exploratory study of CD patients undergoing ileocecal resection or colonoscopy between 6/2020 and 1/2023, we analysed tissue levels of anti-TNF, anti-TNF antibodies, and cytokines (TNF-α, IL-17, IL-1β, IFN-γ) from intestinal biopsies. Mixed-effects regression models, adjusted for potential confounders,nwere used. Data from 27 CD patients (18 females, 66.7%) were analysed. Fourteen (52%) received adalimumab (ADA) and thirteen received infliximab (IFX), with a median therapy duration of 17 (IQR 4.5–41.5) months. Higher levels of free anti-TNF were found in macroscopically inflamed tissue compared to non-inflamed tissue (β=3.42, 95% CI 1.05–6.10). No significant association was found between serum and tissue anti-TNF levels (β= −0.06, 95% CI −0.70–0.58). Patients treated longernwith anti-TNF had increased IL-17 levels (β=0.19, 95% CI 0.05–0.33), independent of disease duration and age. IFN-γ levels were linked with both follow-up duration and anti-TNF length. Our study shows significantly higher free drug levels in inflamed tissue. Long-term anti-TNF treatment has been linked to increased IL-17 levels, suggesting a possible impact on the cytokine response pathway. We did not observe a relationship between serum and tissue anti-TNF levels.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

<a href="/cs/project/EH22_008%2F0004597" target="_blank" >EH22_008/0004597: Mluvíme s mikroby - porozumění mikrobiálním interakcím v konceptu One Health</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scientific Reports

ISSN

2045-2322

e-ISSN

2045-2322

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1138

Kód UT WoS článku

001393111000023

EID výsledku v databázi Scopus

2-s2.0-85214207190